Perjeta: Data Supports Fast Approval For Breast Cancer Drug, FDA Reviewers Say
Since there are no approved neoadjuvant breast cancer treatments, there is technically no standard of care. However, the
perjeta data supports fast approval breast cancer drug fda reviewers approve neoadjuvant breast cancer treatment technically standard care